Dongxue Lu1,2, Jing Yan3, Feng Liu4, Pinpin Ding5, Bingyu Chen1,2, Yin Lu6, Zhiguang Sun7. 1. First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China. 2. Gastroenterology department, Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. 3. Key Laboratory for Metabolic Diseases in Chinese Medicine, First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China. 4. Department of Orthopaedics, Nanjing Pukou District Chinese Medicine Hospital. 5. Respiratory department, Changzhou Chinese Medicine Hospital, Changzhou, China. 6. Jiangsu Provincial Key Laboratory of Efficacy and Safety Evaluation of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China. 7. First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China. pr_zhiguangsun@163.com.
Abstract
BACKGROUND AND OBJECTIVES: To systematically assess the safety and effectiveness of probiotics in preventing and treating chemotherapy-induced diarrhea (CID), so as to provide the evidence-based evidence for clinical practice. METHODS AND STUDY DESIGN: Electronic databases, including EMbase, Cochrane Library, pubMed, CNKI, VIP, CBM, and Wanfang databases, were retrieved to search for the randomized controlled trials (RCTs) of CIDs among patients with malignant tumors treated with probiotics as of March 2019. Later, the Rev Man 5.3 statistical software was employed to extract data and assess the quality of the identified literature for metaanalysis. RESULTS: Finally, 13 RCTs involving a total of 1024 patients were included into the current metaanalysis. Results of this meta-analysis showed that the addition of probiotics to conventional symptomatic treatment could evidently reduce the total diarrhea rate in patients with cancer [RR=0.47, 95% CI (0.35, 0.63), p<0.00001] and grade III-IV diarrhea [RR=0.16, 95% CI (0.05, 0.42), p=0.0008], increase the total effective rate [OR=4.26, 95% CI (2.55, 7.12), p<0.00001], and shorten the duration of diarrhea [MD=-1.92, 95% CI (-1.96, - 1.88), p<0.00001]; meanwhile, the difference was statistically significant. But in patients with grade I-II diarrhea [RR=0.81, 95% CI (0.53, 1.24), p=0.34], the difference was not statistically significant. Besides, none of the enrolled study had reported adverse reactions. CONCLUSIONS: The application of probiotics before or during chemotherapy can effectively prevent the occurrence of CID among cancer patients. Moreover, the combination of probiotics in treating CID can also improve the therapeutic effect on CID, with less adverse events.
BACKGROUND AND OBJECTIVES: To systematically assess the safety and effectiveness of probiotics in preventing and treating chemotherapy-induced diarrhea (CID), so as to provide the evidence-based evidence for clinical practice. METHODS AND STUDY DESIGN: Electronic databases, including EMbase, Cochrane Library, pubMed, CNKI, VIP, CBM, and Wanfang databases, were retrieved to search for the randomized controlled trials (RCTs) of CIDs among patients with malignant tumors treated with probiotics as of March 2019. Later, the Rev Man 5.3 statistical software was employed to extract data and assess the quality of the identified literature for metaanalysis. RESULTS: Finally, 13 RCTs involving a total of 1024 patients were included into the current metaanalysis. Results of this meta-analysis showed that the addition of probiotics to conventional symptomatic treatment could evidently reduce the total diarrhea rate in patients with cancer [RR=0.47, 95% CI (0.35, 0.63), p<0.00001] and grade III-IV diarrhea [RR=0.16, 95% CI (0.05, 0.42), p=0.0008], increase the total effective rate [OR=4.26, 95% CI (2.55, 7.12), p<0.00001], and shorten the duration of diarrhea [MD=-1.92, 95% CI (-1.96, - 1.88), p<0.00001]; meanwhile, the difference was statistically significant. But in patients with grade I-II diarrhea [RR=0.81, 95% CI (0.53, 1.24), p=0.34], the difference was not statistically significant. Besides, none of the enrolled study had reported adverse reactions. CONCLUSIONS: The application of probiotics before or during chemotherapy can effectively prevent the occurrence of CID among cancerpatients. Moreover, the combination of probiotics in treating CID can also improve the therapeutic effect on CID, with less adverse events.
Authors: Aleksandra Garczyk; Iwona Kaliciak; Konstanty Drogowski; Paulina Horwat; Stanisław Kopeć; Zuzanna Staręga; Paweł Bogdański; Marta Stelmach-Mardas; Marcin Mardas Journal: J Clin Med Date: 2022-06-14 Impact factor: 4.964
Authors: Ifeoma Julieth Dikeocha; Abdelkodose Mohammed Al-Kabsi; Salasawati Hussin; Mohammed Abdullah Alshawsh Journal: BMJ Open Date: 2020-08-07 Impact factor: 2.692